Climb Bio, Inc. (CLYM) Form 424B5 — Jun 12, 2026
Climb Bio, Inc. (CLYM) filed a prospectus supplement to register the sale of up to $100 million of its common stock through an at-the-market (ATM) offering. The company entered into an Open Market Sale Agreement with Jefferies LLC, which will act as sales agent and receive a commission of up to 3.0% of gross proceeds. The filing references a last reported sale price of $10.91 per share on June 11, 2026.
Key figures
- Cash Position
- 148100000
- Gross Proceeds
- 100000000
- Offering Price
- 10.91
- Shares Outstanding
- 47768543
- Sales agent commission
- 3.0%
- Pro forma ntbv per share
- 4.39
- Estimated offering expenses
- 400000
- Immediate dilution per share
- 5.67
- Net tangible book value per share
- 3.1
Price after filing
1 day: 0.0%7 days: +4.9%30 days: +26.7%
Close on the filing date to close N calendar days later (from $10.91). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.